Breakthrough drugs spark call for PBS re-think
9th December 2014
Australia needs to find a way to fund breakthrough drugs like the new generation of immune-activating cancer therapies, says Professor Grant McArthur, head of translational research at the Peter MacCallum Cancer Centre in Melbourne.
Using unusually enthusiastic language, he describes the PD-1 inhibitors Pembrolizumab from Merck and nivolumab from Bristol-Myers Squibb as potential game changers.
“It’s a paradigm shift for melanoma treatment and very significant for the field of oncology.”
He says three trials presented at
